Chongqing Precision Biotech Co., Ltd
Clinical trials sponsored by Chongqing Precision Biotech Co., Ltd, explained in plain language.
-
Engineered immune cells take aim at Hard-to-Treat leukemias
⭐️ CURE ⭐️ CompletedThis trial is testing a new type of immune cell therapy called CD123 CAR-NK cells in people with relapsed or refractory acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN). The cells are designed to find and attack cancer cells that carry a protei…
Phase: PHASE1, PHASE2 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: ⭐️ CURE ⭐️
Last updated Aug 07, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control CompletedThis trial investigates a type of immunotherapy called CAR-T cells that are designed to recognize and attack cancer cells carrying a protein called CEA. The study includes adults with advanced gastric, colon, rectal, esophageal, or pancreatic cancer who have not responded to at l…
Phase: PHASE1, PHASE2 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tests a new type of cell therapy called CEA-targeted CAR-T for people with advanced colorectal, esophageal, stomach, or pancreatic cancers that have stopped responding to standard treatments. The therapy involves taking a patient's own immune cells, enginee…
Phase: PHASE1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC